Pharmaceutical giants are once again acquiring smaller biotechnology companies after a lull in activity — deals that become a lot easier for drug companies to stomach after the Republican tax overhaul allowed them to repatriate overseas cash.
Here are some of the most recent pharma deals:
Today: French drug maker Sanofi agreed to buy Ablynx for $4.8 billion, just one week after it said it is buying Bioverativ for $11.6 billion.
Jan. 22: Celgene acquired Juno Therapeutics for $9 billion, cementing its spot in the CAR-T race for developing innovative, and expensive, cancer therapies. The Juno deal came just weeks after Celgene nabbed Impact Biosciences for up to $7 billion.
2017: It was slow, but Gilead made noise with its $11.9 billion deal for Kite Pharma.